Skip to main content

Frontotemporal Dementia clinical trials at UCLA

2 in progress, 1 open to eligible people

Showing trials for
  • ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)

    open to eligible people ages 18 years and up

    ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) represents the formalized integration of ARTFL (U54 NS092089; funded through 2019) and LEFFTDS (U01 AG045390; funded through 2019) as a single North American research consortium to study FTLD for 2019 and beyond.

    Los Angeles 5368361, California 5332921 and other locations

  • Intranasal Oxytocin for Frontotemporal Dementia

    Sorry, in progress, not accepting new patients

    The purpose of this study is to assess the safety, tolerability and effects on behaviour of Syntocinon given intranasally (by a spray into the nostrils) compared to placebo (an inactive saline substance that contains no medication) in participants with frontotemporal dementia/Pick's disease. This study will take place in approximately 15 centres across Canada and the United States. Approximately 112 patients in total will be enrolled in this study. In the first phase we will examine which of three different dosing schedules of oxytocin may be more effective. In the second phase of the study, patients entering the study will be randomized to the oxytocin dosing schedule that appeared most effective in the first phase.

    Los Angeles 5368361, California 5332921 and other locations

Our lead scientists for Frontotemporal Dementia research studies include .

Last updated: